Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milind Kulkarni

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Pragmatic and Observational Research|August 17, 2022
A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1Ameet Dravid, Dnyanesh Morkar, Dwijendra Prasad, et al.
Human Vaccines & Immunotherapeutics|October 22, 2024
Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in IndiaAnuradha S Tripathy, Dharmendra Singh, Diptee Trimbake, et al.
Human Vaccines & Immunotherapeutics|December 28, 2022
Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six monthsRima R Sahay, Pragya D Yadav, Ashok Nandapurkar, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Pragmatic and Observational Research|August 17, 2022
A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1Ameet Dravid, Dnyanesh Morkar, Dwijendra Prasad, et al.
Human Vaccines & Immunotherapeutics|October 22, 2024
Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in IndiaAnuradha S Tripathy, Dharmendra Singh, Diptee Trimbake, et al.
Human Vaccines & Immunotherapeutics|December 28, 2022
Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six monthsRima R Sahay, Pragya D Yadav, Ashok Nandapurkar, et al.
Pageof 4